Rectal adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Rectal adenocarcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Phase II Study of Intratumoral Hydrogen Peroxide (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer https://clinicaltrials.eu/trial/phase-ii-study-of-intratumoral-hydrogen-peroxide-krc-01-combined-with-radiotherapy-for-locally-advanced-rectal-cancer/ Sun, 31 May 2026 04:02:42 +0000 https://clinicaltrials.eu/trial/phase-ii-study-of-intratumoral-hydrogen-peroxide-krc-01-combined-with-radiotherapy-for-locally-advanced-rectal-cancer/ Locally advanced high‑risk stage III rectal adenocarcinoma (non‑metastatic) is a type of cancer that has grown through the wall of the rectum but has not spread to other parts of the body. The study uses a combination of external beam radiotherapy and injections of KRC-01, an investigational product that contains hydrogen peroxide and is given directly into the tumor (intratumoral injection). The aim is to shrink or eliminate the tumor while trying to keep the rectum intact.

The purpose is to determine how often patients achieve a clinical complete response, meaning that after treatment no tumor can be felt or seen on exams. Participants receive a series of radiation sessions over several weeks together with several KRC-01 injections, followed by visits to check the tumor with imaging and questionnaires about quality of life at about week 6 and week 24. Safety and side effects are recorded, and blood and tissue samples are collected to look for markers that might predict how well the treatment works.

]]> Study of drug combination with radiotherapy versus radiotherapy alone for locally advanced rectal cancer in patients 75 years and older https://clinicaltrials.eu/trial/study-of-drug-combination-with-radiotherapy-versus-radiotherapy-alone-for-locally-advanced-rectal-cancer-in-patients-75-years-and-older/ Wed, 29 Apr 2026 15:08:06 +0000 https://clinicaltrials.eu/trial/study-of-drug-combination-with-radiotherapy-versus-radiotherapy-alone-for-locally-advanced-rectal-cancer-in-patients-75-years-and-older/ This study involves patients aged 75 years and older who have been diagnosed with rectal adenocarcinoma, which is a type of cancer that develops in the rectum. The rectum is the last part of the large intestine before the anus. The study focuses on patients whose cancer has grown to a certain size or depth in the rectal wall, making it locally advanced. The treatments being evaluated include short-course radiotherapy, which is a form of radiation treatment given over a shorter period of time, followed by chemotherapy using a combination of medications called FOLFOX, which consists of oxaliplatin, fluorouracil, and either folinic acid or calcium levofolinate. These medications are given through a vein to help shrink the cancer. The study will compare two treatment approaches: one group will receive radiotherapy followed by six cycles of chemotherapy, while the other group will receive only radiotherapy without additional chemotherapy.

The purpose of this study is to determine which treatment approach is more effective in preserving the organ, meaning avoiding the need for surgery to remove the rectum. The study will track patients for 24 months to see how many are able to avoid having surgery called total mesorectal excision, which involves removing the rectum and surrounding tissue. After receiving their assigned treatment, patients will be monitored through various examinations including physical examinations of the rectum, imaging scans using magnetic resonance imaging and computed tomography, and endoscopic evaluations where a camera is used to look inside the rectum. The study will assess whether the cancer has completely disappeared, partially shrunk, or remained stable, and whether patients can be managed without immediate surgery through careful monitoring.

Throughout the study, doctors will evaluate the safety of the treatments by monitoring for side effects and complications. They will also assess how well patients are functioning in their daily lives, their bowel function, and their overall quality of life using questionnaires at several time points during the study. For patients who do require surgery, either as part of the initial treatment plan or later if the cancer returns, the study will evaluate surgical outcomes and any complications that may occur. The study will also track whether the cancer spreads to other parts of the body, whether it returns in the area where it was originally located, and overall survival rates at 24 months.

]]> Study on Oxaliplatin and Capecitabine for Patients with Locally Advanced Rectal Cancer https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-capecitabine-for-patients-with-locally-advanced-rectal-cancer/ Wed, 29 Apr 2026 15:01:03 +0000 https://clinicaltrials.eu/trial/study-on-oxaliplatin-and-capecitabine-for-patients-with-locally-advanced-rectal-cancer/ This clinical trial is focused on studying a type of cancer called locally advanced rectal cancer, specifically a form known as adenocarcinoma that occurs in the middle or lower part of the rectum. The study is investigating a treatment approach that does not involve surgery. Instead, it uses a combination of medications and therapies to treat the cancer. The medications being studied are Oxaliplatin and Capecitabine, which are both chemotherapeutic drugs. These drugs are used to kill cancer cells or stop them from growing and spreading.

The purpose of the study is to determine if this non-surgical treatment approach is effective in preventing the cancer from coming back in other parts of the body. Participants in the study will receive a combination of treatments, including Induction Chemotherapy (ICT) and Chemo-Radiotherapy (CRT), followed by a period of close monitoring without surgery. The study will also look at various markers in the blood and tissue to understand how the treatment affects the cancer and the surrounding tissue.

Throughout the study, participants will be closely monitored to assess their response to the treatment. The study aims to evaluate the rate of complete response, meaning the cancer is no longer detectable, as well as the overall survival and quality of life of the participants. The study will also track any recurrence of the cancer and the ability to preserve the organs affected by the cancer. This research hopes to provide valuable insights into the effectiveness of non-surgical treatments for locally advanced rectal cancer.

]]> Study on Contact X-ray Brachytherapy with Capecitabine for Rectal Cancer Preservation in Adults with Intermediate Stage Rectal Adenocarcinoma https://clinicaltrials.eu/trial/study-on-contact-x-ray-brachytherapy-with-capecitabine-for-rectal-cancer-preservation-in-adults-with-intermediate-stage-rectal-adenocarcinoma/ Wed, 29 Apr 2026 14:26:23 +0000 https://clinicaltrials.eu/trial/study-on-contact-x-ray-brachytherapy-with-capecitabine-for-rectal-cancer-preservation-in-adults-with-intermediate-stage-rectal-adenocarcinoma/ This clinical trial is focused on studying a type of cancer called rectal adenocarcinoma, which affects the rectum, a part of the large intestine. The study is specifically looking at cases where the cancer is at an intermediate stage, meaning it is not too small or too large. The main goal of the trial is to see if a treatment called contact X-ray brachytherapy can help preserve the rectum while increasing survival rates. This treatment is being tested in combination with a series of therapies known as total neoadjuvant therapy (TNT), which is a comprehensive approach to treating cancer before surgery.

The trial involves several medications that are commonly used in cancer treatment. These include Capecitabine, which is taken orally as a tablet, and Oxaliplatin, Irinotecan Hydrochloride Trihydrate, Folinic Acid, and Fluorouracil, which are administered through infusions or injections. The study will compare the effects of these medications, along with the contact X-ray brachytherapy, to see if they can effectively treat the cancer while allowing patients to keep their rectum intact.

Participants in the study will receive these treatments over a period of time, and their health will be monitored to assess the effectiveness of the therapy. The study aims to find out if this combination of treatments can help patients live longer without needing major surgery to remove the rectum. The trial will also look at other factors like the quality of life and any side effects that may occur during the treatment process.

]]>